By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



11025 Roselle Street
Suite 200
San Diego  California  92121  U.S.A.
Phone: 858-587-5870 Fax: 858-587-5871


Company News
Study Shows Use Of 20/20 GeneSystems, Inc.’ Breast Cancer Indexsm Molecular Test Substantially Lowers Medical Costs For ER+ Breast Cancer Patients Compared With Standard Management 9/11/2014 10:07:53 AM
bioTheranostics Announces Update To Its bioT3 Metastatic Cancer Solution 8/12/2014 8:26:37 AM
bioTheranostics Names Ramesh Hariharan As Vice President Of Marketing 7/23/2014 12:12:05 PM
bioTheranostics Receives Approval To Perform Breast Cancer Index Testing For Patients In State Of New York 7/16/2014 10:29:02 AM
bioTheranostics’ Cancertype ID® Molecular Test Is A Cost-Effective Approach To Standardizing Diagnosis & Improving Metastatic Cancer Care, Study Shows 7/14/2014 6:33:02 AM
bioTheranostics Announces Agreement With National PPO Network Fedmed 7/10/2014 6:23:36 AM
Head-To-Head Evidence Versus Oncotype Dx Further Demonstrates Superior Clinical Accuracy Of bioTheranostics’ Breast Cancer Index For ER+ Patients 6/3/2014 9:43:18 AM
bioTheranostics Signs Agreement With National PPO Network Prime Health Services 4/9/2014 9:25:12 AM
bioTheranostics’ New Biot3 Metastatic Cancer Solution Provides Comprehensive Genomic Testing With Integration Of Next Generation Sequencing 2/3/2014 12:32:39 PM
bioTheranostics Signs Collaboration Agreement With Top U.S. Hospital and Reference Laboratory to Offer CancerTYPE ID® Molecular Test for Metastatic Cancer 10/29/2013 9:54:47 AM